What type of study is this?

September 28, 2025Frontiers in MedicineOpen Access

Efficacy and safety of cyclosporine a combined with acitretin in moderate-to-severe plaque psoriasis: a randomized controlled trial

View Full Paper

Ask AI

Bookmark

Authors

KXKang Xu PYPing Yuan SJSujie Jia

Discussion

Member takes

Overview

Randomized controlled trial demonstrated that combination therapy improves PASI scores in psoriasis patients, indicating promising treatment efficacy.

Key Points

Combination therapy achieved superior PASI75 responses at week 4, with over 60% of patients improving, compared to less than 25% in monotherapy groups.
At week 12, 89.2% of patients in the combination group achieved PASI75, while 66.7% reached PASI90, showing sustained benefits over time.
Treatment primarily focused on PASI reductions, while secondary outcomes like DLQI and BSA improvements showed a similar pattern of efficacy.
Combination therapy overall showed an acceptable safety profile, with most adverse events being mild and reversible.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/68d9052941e1c178a14f571d https://doi.org/10.3389/fmed.2025.1667058

View Full Paper

Ask AI

Bookmark

September 28, 2025Frontiers in MedicineOpen Access

Efficacy and safety of cyclosporine a combined with acitretin in moderate-to-severe plaque psoriasis: a randomized controlled trial

View Full Paper

Ask AI

Bookmark

Authors

KXKang Xu PYPing Yuan SJSujie Jia

Discussion

Member takes

Overview

Randomized controlled trial demonstrated that combination therapy improves PASI scores in psoriasis patients, indicating promising treatment efficacy.

Key Points

Combination therapy achieved superior PASI75 responses at week 4, with over 60% of patients improving, compared to less than 25% in monotherapy groups.
At week 12, 89.2% of patients in the combination group achieved PASI75, while 66.7% reached PASI90, showing sustained benefits over time.
Treatment primarily focused on PASI reductions, while secondary outcomes like DLQI and BSA improvements showed a similar pattern of efficacy.
Combination therapy overall showed an acceptable safety profile, with most adverse events being mild and reversible.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/68d9052941e1c178a14f571d https://doi.org/10.3389/fmed.2025.1667058

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark